Synapse - Gastrointestinal Oncology Service

Results (1290)

Body mass index and somatic variants in biliary tract cancers

Meeting Abstract

Al Mahmasani, L.; Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer

Meeting Abstract

Cassier, P. A.; Van Laethem, J. L.; Borbath, I.; Macarulla, T.; Geboes, K. P.; Lambert, A.; Prenen, H.; Mitry, E.; Blanc, J. F.; Feliu, J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2(+)advanced solid tumors

Meeting Abstract

Sohal, D.; Iqbal, S.; Turcotte, S.; Botta, G. P.; Schlechter, B. L.; Ku, G. Y.; Hosein, P. J.; Saibil, S.; Gavriliuc, M.; Apostolopoulou, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: The phase III, randomized LEAP-015 study

Journal Article

Shitara, K.; Lorenzen, S.; Li, J.; Bai, Y. X.; Fernández, M. G.; Aguilar, M.; Shoji, H.; Reyes-Cosmelli, F.; Peña, Y. R.; Corrales, L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses

Meeting Abstract

Elez, E.; Yoshino, T.; Shen, L.; Lonardi, S.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)

Meeting Abstract

Char, S. K.; Shi, Q.; Zemla, T.; Ma, C.; Cheng, E.; Kumthekar, P.; Guthrie, K. A.; Couture, F.; Kuebler, J. P.; Kumar, P.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors

Meeting Abstract

Chung, V.; Kochenderfer, M. D.; Natarajan, N.; Williams, G. R.; Laursen, A. A.; Cockrum, P.; Rhodes, W.; Surinach, A.; Zhang, L.; Li, J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers

Meeting Abstract

Schreck, K. C.; De La Fuente, M. I.; Rine, J.; Kline, I.; Shephard, S. P.; Ahnert, J. R.; Sherman, E. J.; Yaeger, R.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)

Meeting Abstract

Sinicrope, F. A.; Ou, F. S.; Arnold, D.; Peters, W.; Behrens, R. J.; Lieu, C. H.; Matin, K.; Cohen, D. J.; Potter, S. L.; Frankel, W. L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)

Meeting Abstract

Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L.; Oh, D.; Omori, T.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save